Clinical Trial Update: A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating liquid certolizumab pegol added to methotrexate for rheumatoid arthritis to reduce signs and symptoms and prevent joint damage; study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Certolizumab pegol (liquid) (certolizumab pegol)

Snippet

Sponsor: UCB Pharma | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED